At LiverRight, we’ve built our clinic around one core idea: early detection changes outcomes.
Whether it’s diagnosing MASLD/NASH in its earliest, reversible stages or accelerating access to specialist care across all 50 states, our goal has always been to make hepatology accessible, data-driven, and patient-centered.
Today we’re announcing a major expansion of that mission. LiverRight is partnering with HelioLiver to integrate a cutting-edge, blood-based liver cancer screening test into our telehealth workflow—making it easier than ever for at-risk patients to get answers sooner.
Why This Matters
Liver cancer is notoriously difficult to detect early. Traditional surveillance, often based on routine imaging every six months, misses a large share of early tumors. HelioLiver’s multi-analyte blood test, now available as a laboratory-developed test (LDT), has been shown in clinical settings to detect early hepatocellular carcinoma with greater sensitivity than standard methods.
By offering this test through LiverRight virtual visits, we’re removing two of the biggest barriers to early detection: access and convenience. High-risk patients—people living with cirrhosis, chronic viral hepatitis, MASLD/MASH, or other predispositions—can now start screening with a simple telemedicine visit followed by a HelioLiver test prescribed directly by their LiverRight provider.
How It Works
- Book a LiverRight consultation.
Start with a same-week or near-term telemedicine visit with one of our liver specialists to assess your risk and care plan. Learn more or schedule here: https://liverright.com/book. - HelioLiver screening.
If appropriate, your provider will prescribe the HelioLiver blood test—a non-invasive “liquid biopsy” designed to detect cancer biomarkers early. - Next steps with advanced imaging.
Patients with positive or concerning results can be guided to advanced imaging (such as an MRI with AI-powered analysis) to confirm and stage disease.
This integration reflects our broader approach at LiverRight: preventative hepatology, not just reactive care. From understanding why sleep patterns may correlate with liver disease to exploring the spectrum of early, reversible liver damage in our blog, we strive to help patients and clinicians act earlier and more intelligently.
A Smarter Standard of Care
We see telemedicine not as a stopgap, but as a strategic advantage. It allows us to drive the kind of early diagnosis and longitudinal engagement that researchers and clinicians say is essential in liver disease—before symptoms arise and when interventions are most effective.
Combining LiverRight’s virtual platform with HelioLiver’s advanced screening moves us further in that direction. Early detection of liver cancer isn’t just a clinical aspiration—it’s a tangible possibility for more patients today.
We’ll be sharing more insights on this partnership and how it fits into our broader care philosophy on the LiverRight blog. Stay tuned, and as always, reach out to our team if you have questions or want to schedule a visit: https://liverright.com/book.